Latest Unica Corporation Stories
WALTHAM, Mass., June 11, 2014 /PRNewswire/ -- Rocket Software (www.rocketsoftware.com) today announced that vice president
AUSTIN, TEXAS, May 2 /PRNewswire/ - Affinium Pharmaceuticals announced today the results of a new multiple ascending dose Phase I study of its novel, selective-spectrum, anti-staphylococcal agent, AFN-1252 in a novel oral formulation. The study examined the tolerability, safety and pharmacokinetics of immediate release tablets of AFN-1252.
AUSTIN, March 15 /PRNewswire/ - Affinium Pharmaceuticals, a clinical-stage drug development company with a novel, specific-spectrum anti-staphylococcal antibiotic, announced today that Dr. Barry Hafkin, Chief Medical Officer, and Dr.
ARMONK, N.Y., Oct.
ARMONK, N.Y. and WALTHAM, Mass., Aug.
AUSTIN, TX, April 12 /PRNewswire/ - Affinium Pharmaceuticals announced today the commencement of a Phase I study in the United States for its novel molecular entity, AFN-1252, a first in class antibiotic candidate focused on the oral and IV treatment of susceptible and highly resistant strains of Staphylococcus aureus (MRSA).
Long-standing Unica partner continues to invest and grow relationship by joining enhanced program WAKEFIELD, Mass., Oct.
NEW YORK, Sept. 8 /PRNewswire/ -- Tervela, the leading provider of open, intelligent, hardware-accelerated messaging systems, today named Eric R. Schnadig as chief executive officer, succeeding J. Barry Thompson, Tervela's founder, who takes over as chief technology officer. Mr.
NEW YORK, Jan.